A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis

Clinical Science

Volumn 131, Issue 10, 2017, Pages 935-949

  Arrieta1, Vanessa ^a   Martinez Martinez, Ernesto ^a   Ibarrola, Jaime ^a   Alvarez, Virginia ^a   Sádaba, Rafael ^a   Garcia Peña, Amaia ^a   Fernández Celis, Amaya ^a   Cachofeiro, Victoria ^b   Rossignol, Patrick ^c   López Andrés, Natalia ^a,c  

^a Atención Primaria Y Promoción de La Salud   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; CD3 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GALECTIN 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MODIFIED CITRUS PECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSIN HEAVY CHAIN BETA; OSTEOPONTIN; POLYSACCHARIDE; PROTEIN; PROTEIN C FOS; PROTEIN INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTIC STENOSIS; AORTIC VALVE REPLACEMENT; AUTOPSY; BODY WEIGHT; CARDIAC MUSCLE CELL; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART STROKE VOLUME; HEART TISSUE; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERVENTRICULAR SEPTUM; MALE; MOLECULAR PATHOLOGY; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SUPRAVALVULAR AORTIC STENOSIS; SYSTOLIC BLOOD PRESSURE; UPREGULATION; ANIMAL; AORTIC VALVE STENOSIS; DISEASE MODEL; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREGNANCY; VERY ELDERLY; WISTAR RAT;

AGED; AGED, 80 AND OVER; ANIMALS; AORTIC VALVE STENOSIS; DISEASE MODELS, ANIMAL; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; PREGNANCY; RATS; RATS, WISTAR; VENTRICULAR REMODELING;

EID: 85018451933     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20170145     Document Type: Review

References (22)

1. Ziaeian, B. and Fonarow, G.C. (2016) Epidemiology and aetiology of heart failure. Nat. Rev. Cardiol. 13, 368-378.
2. Iung, B., Baron, G., Butchart, E.G., Delahaye, F., Gohlke-Barwolf, C., Levang, O.W. et al. (2003) A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur. Heart J. 24, 1231-1243.
3. Danielsen, R., Aspelund, T., Harris, T.B. and Gudnason, V. (2014) The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES-Reykjavik study. Int. J. Cardiol. 176, 916-922.
4. Bosse, Y., Miqdad, A., Fournier, D., Pepin, A., Pibarot, P. and Mathieu, P. (2009) Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ. Cardiovasc. Genet. 2, 489-498.
5. Dweck, M.R., Boon, N.A. and Newby, D.E. (2012) Calcific aortic stenosis: a disease of the valve and the myocardium. J. Am. Coll. Cardiol. 60, 1854-1863.
6. Heusch, G., Libby, P., Gersh, B., Yellon, D., Böhm, M., Lopaschuk, G. et al. (2014) Lancet seminar: cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383, 1933-1943.
7. Yu, L., Ruifrok, W.P., Meissner, M., Bos, E.M., van Goor, H., Sanjabi, B. et al. (2013) Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 6, 107-117.
8. Calvier, L., Miana, M., Reboul, P., Cachofeiro, V., Martinez-Martinez, E., de Boer, R.A. et al. (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler. Thromb. Vasc. Biol. 33, 67-75.
9. Calvier, L., Martinez-Martinez, E., Miana, M., Cachofeiro, V., Rousseau, E., Sadaba, J.R. et al. (2015) The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 3, 59-67.
10. Martinez-Martinez, E., Calvier, L., Fernandez-Celis, A., Rousseau, E., Jurado-Lopez, R., Rossoni, L.V. et al. (2015) Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension 66, 767-775.
11. Martinez-Martinez, E., Lopez-Andres, N., Jurado-Lopez, R., Rousseau, E., Bartolome, M.V., Fernandez-Celis, A. et al. (2015) Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension 66, 961-969.
12. Glinsky, V.V. and Raz, A. (2009) Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr. Res. 344, 1788-1791.
13. Sharma, U.C., Pokharel, S., van Brakel, T.J., van Berlo, J.H., Cleutjens, J.P., Schroen, B. et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110, 3121-3128.
14. Schunkert, H., Dzau, V.J., Tang, S.S., Hirsch, A.T., Apstein, C.S. and Lorell, B.H. (1990) Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J. Clin. Invest. 86, 1913-1920.
15. Feldman, A.M., Weinberg, E.O., Ray, P.E. and Lorell, B.H. (1993) Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ. Res. 73, 184-192.
16. Weinberg, E.O., Schoen, F.J., George, D., Kagaya, Y., Douglas, P.S., Litwin, S.E. et al. (1994) Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90, 1410-1422.
17. Litwin, S.E., Katz, S.E., Weinberg, E.O., Lorell, B.H., Aurigemma, G.P. and Douglas, P.S. (1995) Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 91, 2642-2654.
18. Cioffi, G., Faggiano, P., Vizzardi, E., Tarantini, L., Cramariuc, D., Gerdts, E. et al. (2011) Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart 97, 301-307.
19. Sharma, U.C., Pokharel, S., van Brakel, T.J., van Berlo, J.H., Cleutjens, J.P., Schroen, B. et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110, 3121-3128.
20. Wu, C.K., Su, M.Y., Lee, J.K., Chiang, F.T., Hwang, J.J., Lin, J.L. et al. (2015) Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci. Rep. 5, 17007.
21. Zhou, K., Zhou, Y., Zhao, Y., Tan, C., Yuan, Z., Li, J. et al. (2016) The relationship between galectin-3 and different patterns of ventricular geometry remodelling in aortic valve stenosis. Heart Lung Circ 25, 371-377.
22. Baldenhofer, G., Zhang, K., Spethmann, S., Laule, M., Eilers, B., Leonhardt, F. et al. (2014) Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). Int. J. Cardiol. 177, 912-917.